Actively Recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Led by Valencia Technologies Corporation · Updated on 2026-01-28
200
Participants Needed
22
Research Sites
248 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to assess the long-term safety and effectiveness of the FDA-approved eCoin4 implanted tibial nerve stimulator in people with overactive bladder (OAB) who experience urgency urinary incontinence (UUI). The study is prospective, involves multiple centers, and follows a single group of participants to understand how the device performs in real-world use. Participants will receive an implant of the eCoin device, which provides subcutaneous stimulation to the tibial nerve. This stimulation is intended to help manage urgency urinary incontinence. The treatment involves implanting the device and then monitoring participants over time to evaluate its safety and effectiveness. Throughout the study, participants will complete voiding diaries and quality of life questionnaires during follow-up visits that extend up to 5 years. Researchers will monitor safety by tracking any device- or procedure-related adverse events and measure effectiveness by assessing responder rates at 12 and 24 months. The study includes ongoing evaluations of safety data even after reimplantation when applicable, ensuring comprehensive long-term monitoring.
CONDITIONS
Brief Title
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population
- Diagnosis of overactive bladder with urgency urinary incontinence
- At least one urgency urinary incontinence episode on each of three days as recorded in a 3-day voiding diary
- Written informed consent provided
- Mentally competent and able to understand all study requirements
- Willing and able to complete a 3-day voiding diary and quality of life questionnaire
- Without pharmacological treatment for overactive bladder for at least 2 weeks prior to baseline or longer if therapeutic effect persists
- Intolerant of or inadequate response to anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or previous percutaneous tibial nerve stimulation
- Suitable surgical candidate as determined by physician
- Appropriate for eCoin treatment based on US FDA-approved instructions for use
You will not qualify if you...
- Not appropriate for eCoin therapy based on US FDA-approved instructions for use
- Clinically significant bladder outlet obstruction
- Predominant stress urinary incontinence (more than one-third of leaks on baseline diary)
- Active urinary tract infection at enrollment
- Known polyuria
- Significant lower urinary tract pain or diagnosis of interstitial cystitis or bladder pain syndrome
- Abnormal post void residual volume greater than 200 cc
- Clinically significant urethral stricture disease or bladder neck contracture
- Chronic venous insufficiency with ankle skin changes
- Morbid obesity judged unsuitable for study
- History of bladder, urethral, or prostate cancer
- Anti-stress incontinence sling surgery within the last year
- Pregnant or planning pregnancy during study
- Presence of urinary fistula, bladder stone, or interstitial cystitis
- Uncontrolled diabetes mellitus with Hemoglobin A1C greater than 7 or diabetes with significant complications
- Implantable neurostimulator, pacemaker, or implantable cardiac defibrillator
- Treatment with onabotulinumtoxinA within 9 months before enrollment unless therapeutic effect absent
- Percutaneous tibial nerve stimulation within 4 weeks before enrollment unless therapeutic effect absent
- Current use of transcutaneous electrical nerve stimulation in pelvic region, back, or legs
- Need for MRI scan other than head/neck/shoulder during study
- Clotting or bleeding disorders or anticoagulant therapy judged unsuitable
- Neutropenic or immune-compromised
- Previous surgery or significant scarring at implant site
- Ongoing dermatologic condition at implant site
- Clinically significant peripheral neuropathy in lower extremities
- Neurogenic bladder dysfunction
- Pitting edema at implant location of grade 2 or higher
- Inadequate skin integrity or infection/inflammation in lower leg
- Symptomatic varicose veins
- Open wounds, trauma, or prior surgery in lower extremities
- Arterial disease or vasculitis in lower extremities
- Bladder stones or neoplasia
- Any condition judged by investigator to make participant unsuitable for study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure with ongoing device use
Participants receive the eCoin device implanted for tibial nerve stimulation to treat urgency urinary incontinence.
1 implantation visit (in-person)
Duration - Up to 5 years
Participants complete voiding diaries and questionnaires during follow-up visits to assess safety and effectiveness of the eCoin device over time.
Periodic follow-up visits over 5 years
Trial Site Locations
Total: 22 locations
1
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
Actively Recruiting
2
USA Health
Mobile, Alabama, United States, 36606
Withdrawn
3
Arkansas Urology
Little Rock, Arkansas, United States, 72211
Actively Recruiting
4
University of California, Irvine
Irvine, California, United States, 92697
Actively Recruiting
5
AIR Research
Los Angeles, California, United States, 90017
Actively Recruiting
6
Stanford Health
Stanford, California, United States, 94305
Actively Recruiting
7
Urological Research Network Corp
Hialeah, Florida, United States, 33016
Actively Recruiting
8
The Emory Clinic
Atlanta, Georgia, United States, 30322
Actively Recruiting
9
Rush University
Chicago, Illinois, United States, 60612
Actively Recruiting
10
The Iowa Clinic
Ankeny, Iowa, United States, 50023
Actively Recruiting
11
University of Iowa
Iowa City, Iowa, United States, 52242
Actively Recruiting
12
University of Kansas Medical Center Research Institute, Inc
Kansas City, Kansas, United States, 66160
Actively Recruiting
13
Cypress Medical Research
Wichita, Kansas, United States, 67226
Actively Recruiting
14
Louisiana State University Health Sciences Center
Shreveport, Louisiana, United States, 71103
Active, Not Recruiting
15
Minnesota Urology
Woodbury, Minnesota, United States, 55125
Actively Recruiting
16
Specialty Clinical Research of St. Louis
St Louis, Missouri, United States, 63141
Actively Recruiting
17
Weill Cornell Medicine: Department of Urology
New York, New York, United States, 10065
Actively Recruiting
18
The Oregon Clinic
Portland, Oregon, United States, 97225
Active, Not Recruiting
19
Southern Urogynecology
West Columbia, South Carolina, United States, 29169
Actively Recruiting
20
UPNT Research Institute
Arlington, Texas, United States, 76017
Actively Recruiting
21
Baylor College of Medicine
Houston, Texas, United States, 77030
Actively Recruiting
22
The Methodist Hospital Research Institute
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
Dylan Beyer
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here